针对乳腺癌的CD200:免疫治疗策略的机遇和挑战
1Western Reserve Academy, Hudson, OH 44236, USA.
International journal of molecular sciences
|January 11, 2025
概括
瘤的进展是由免疫抑制的微环境推动的. 针对CD200 (细胞表面糖蛋白) 和它的受体CD200R,通过调节对瘤的免疫反应,提供了有前途的癌症治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 瘤微环境往往会产生免疫抑制,帮助癌症的进展和治疗耐药性.
- 细胞表面糖蛋白CD200通过其受体CD200R在免疫调节中发挥着至关重要的作用.
- CD200-CD200R相互作用抑制了抗瘤免疫活性,促进了癌细胞的免疫逃避.
研究的目的:
- 审查CD200向癌症治疗的最新进展.
- 探索开发针对CD200通路的治疗方法的未来趋势.
- 讨论不同类型癌症中可变CD200通路表达对治疗策略的意义.
主要方法:
- 关于CD200和CD200R在癌症中的最新研究的文献综述.
- 在各种癌症中分析涉及CD200表达的分子途径.
- 对CD200向治疗方法的当前研究的综合.
主要成果:
- CD200-CD200R信号传输是瘤免疫逃避的一个关键机制.
- 向CD200提供了一种潜在的策略,以克服瘤诱导的免疫抑制.
- 了解可变的CD200表达模式对于个性化癌症治疗至关重要.
结论:
- 针对CD200的疗法代表了癌症治疗的有希望的途径.
- 对CD200通路调节的进一步研究可能会导致新的治疗干预措施.
- 该审查强调了考虑分子途径变异对于有效的癌症治疗选择的重要性.
关键词:
CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD2 CD2 CD2 CD2 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD3 CD2 CD4 CD2 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 is included included included included includedCD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R乳腺癌 乳腺癌 乳腺癌免疫逃避 免疫逃避相关概念视频
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Vaccines
337
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
337
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


